Lupin Limited
LUPIN
Rang in Aktien
#2104
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Aktienkurs
$21.45
Marktkapitalisierung
$9.81B
Veränderung (1 Tag)
0.25%
Veränderung (1 Jahr)
-2.78%
Land
IN
Handel Lupin Limited (LUPIN)
Kategorie
Healthcare
P/B-Verhältnis für Lupin Limited (LUPIN)
P/B-Verhältnis zum October 2026 TTM: 4.01
Laut den neuesten Finanzberichten und dem Aktienkurs von Lupin Limited beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 4.01. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 5.20.
P/B-Verlauf für Lupin Limited von 2004 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 4.01 | -22.82% |
| 2025 | 5.20 | 0.14% |
| 2024 | 5.20 | 119.66% |
| 2023 | 2.37 | -15.25% |
| 2022 | 2.79 | -16.71% |
| 2021 | 3.35 | 57.38% |
| 2020 | 2.13 | -15.55% |
| 2019 | 2.52 | -2.50% |
| 2018 | 2.59 | -46.46% |
| 2017 | 4.83 | -19.02% |
| 2016 | 5.96 | -41.29% |
| 2015 | 10.16 | 68.45% |
| 2014 | 6.03 | 10.74% |
| 2013 | 5.45 | -7.55% |
| 2012 | 5.89 | 4.11% |
| 2011 | 5.66 | 3.72% |
| 2010 | 5.46 | 37.73% |
| 2009 | 3.96 | 24.56% |
| 2008 | 3.18 | -42.95% |
| 2007 | 5.57 | -14.64% |
| 2006 | 6.53 | 45.52% |
| 2005 | 4.49 | -25.91% |
| 2004 | 6.06 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 25.60% |
IN
|
